Showing 2621-2630 of 2985 results for "".
- Data Show Acne Patients Don't Understand Risks Associated with Antibiotic Treatmenthttps://practicaldermatology.com/news/data-show-acne-patients-dont-understand-risks-associated-with-antibiotic-treatment/2458805/Widespread and inappropriate use of antibiotics continues to be a problems in the US leading to antibiotic resistance issues. While most people understand how the overuse of antibiotics to treat viral infections contributes to this issue, according to Galderma, new data reveal that acne patients
- Dermatologist Launches Website For Anti-MOC Campaignhttps://practicaldermatology.com/news/dermatologist-launches-website-for-anti-moc-campaign/2458817/Aimed at dermatologists who “believe that board certification should be a one time right of passage and that Maintenance of Certification (MOC) is an undue burden,” a new website from Las Vegas dermatologist H. L. Greenberg, MD encourages board certified dermatologists to si
- Dermatologist Harold Lancer and Ryan Seacrest Collaborate on Male Skincare Linehttps://practicaldermatology.com/news/dermatologist-harold-lancer-and-ryan-seacrest-collaborate-on-male-skincare-line/2458814/Dr. Harold Lancer and radio personality, television host and producer Ryan Seacrest have revealed an exclusive partnership in the burgeoning men's grooming category. They plan to launch a men's skincare line late in 2016. This pairing combines Dr. Lan
- FDA Approves Cotellic Combined with Zelboraf to Treat Advanced Melanomahttps://practicaldermatology.com/news/fda-approves-cotellic-combined-with-zelboraf-to-treat-advanced-melanoma/2458819/The FDA approved Cotellic (cobimetinib) to be used in combination with Zelboraf (vemurafenib) to treat advanced melanoma that has spread to other parts of the body or can’t be removed by surgery, and that has a certain type of abnormal gene (BRAF V600E or V600K mutation). Cotellic w
- Provectus Biopharmaceuticals: Immune Mechanism of Action Data for PV-10 Presented at Society for Immunotherapy of Cancer Annual Meetinghttps://practicaldermatology.com/news/provectus-biopharmaceuticals-immune-mechanism-of-action-data-for-pv-10-presented-at-society-for-immunotherapy-of-cancer-annual-meeting/2458823/Researchers from Moffitt Cancer Center in Tampa, FL, presented a poster titled, “Intralesional Rose Bengal in Melanoma Elicits Tumor Immunity via High Mobility Group Box 1,” at the Society for Immunotherapy of Cancer (SITC) 30th Anniversary Annual Meeting in National Harbor, MD, accor
- Dr. Mandy Honored with ASDS Stegman Awardhttps://practicaldermatology.com/news/dr-mandy-honored-with-asds-stegman-award/2458828/Stephen H. Mandy, M.D., of Miami Beach, FL, was presented recently with the Samuel J. Stegman, MD, Award for Distinguished Service, the highest honor bestowed by the American Society for Dermatologic Surgery (ASDS). The Stegman Award – given to Dr. Mandy during the 2015 ASDS Annual
- Syneron Candela Announces New FDA Clearance for the CO2RE Systemhttps://practicaldermatology.com/news/syneron-candela-announces-new-fda-clearance-for-the-co2re-system/2458825/The FDA has granted numerous additional indications for use of Syneron Medical Ltd.’s CO2RE CO2 device. This clearance, including more than 90 specific indications in total, significantly expands the business opportunity for CO2RE users for high patient dema
- Revance Reports Positive 6-Month Duration for RT002 in BELMONT Studyhttps://practicaldermatology.com/news/revance-reports-positive-6-month-duration-for-rt002-in-belmont-study/2458831/Revance Therapeutics, Inc., shared positive 24-week results from its multi-center BELMONT Phase 2 active comparator study of injectable RT002. The ongoing study for the treatment of glabellar lines in 268 subjects compared the safety, efficacy, and duration of effect of three doses of RT002
- Imlygic Approved for Melanoma; Available in a Weekhttps://practicaldermatology.com/news/imlygic-approved-for-melanoma-available-in-a-week/2458834/The FDA has approved the Biologics License Application for Amgen’s Imlygic™ (talimogene laherparepvec), a genetically modified oncolytic viral therapy indicated for the local treatment of unresectable cutaneous, subcutaneous and nodal lesions in patients with melanoma recurrent after
- Data Demonstrate Efficacy of ON Light Sciences, Inc.'s DeScribe Transparent PFD Patchhttps://practicaldermatology.com/news/data-demonstrate-efficacy-of-on-light-sciences-incs-describe-transparent-pfd-patch/2458839/Results of a clinical study evaluating the potential role of a Perfluorodecalin (PFD)-infused gel patch in laser-assisted tattoo removal were presented at the American Society for Dermatologic Surgery (ASDS) Annual Meeting. “It is estimated that close to 25% of the US population has